Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
3 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.

Tbo-filgrastim more cost-effective than filgrastim for stem cell mobilization, engraftment

21 Dec 2019

Compared with filgrastim, tbo-filgrastim delivers similar efficacy and confers a cost-savings benefit for autologous peripheral blood progenitor cell (PBPC) mobilization and stem cell engraftment, results of a retrospective review have shown.

No statistically significant differences were seen on CD34+ counts during stem cell mobilization, neutrophil engraftment, infection rates during the engraftment phase, nor duration of hospitalization during the engraftment phase.

More patients in the tbo-filgrastim group were administered plerixafor per protocol, which led to more patients meeting their PBPC collection goal in 1 day with fewer collection days overall. However, institutional protocol changes could have confounded this finding.

Use of tbo-filgrastim also resulted in an average cost savings of $2,664.26 per patient ($1,907.33 for PBPC mobilization and $756.93 for stem cell engraftment) when comparing dollars spent on granulocyte colony-stimulating factor products only.

This study included 71 patients who received an autologous haematopoietic stem cell transplant (HSCT) from 1 January 2013 to 31 December 2016 with a documented administration of tbo-filgrastim or filgrastim. The authors retrospectively compared tbo-filgrastim with filgrastim in the autologous HSCT setting approximately 1 year after a system-wide formulary change to the former for all on- and off-label indications.

“Filgrastim, a granulocyte colony-stimulating factor, is commonly used in autologous HSCTs to assist with PBPC collection and to support stem cell engraftment,” the authors said. “In the United States, tbo-filgrastim is approved under its own Biologic License Application and is limited to a single indication excluding the HSCT population.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
3 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.